NCT06774963 - A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Ovarian CancerBreast CancerEndometrial CancerBiliary Tract CancerNon-Small Cell Lung CancerAdvanced or Metastatic Solid Tumors

Interventions

DRUG

LNCB74

LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.

Trial Locations (9)

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

15213

RECRUITING

UPMC, Pittsburgh

22031

RECRUITING

Inova Schar Cancer Institute, Falls Church

63108

RECRUITING

Washington University, Siteman Cancer Center, St Louis

77030

RECRUITING

MD Anderson, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

UT Health San Antonio - MD Anderson Cancer Center, San Antonio

02215

RECRUITING

Dana Farber Cancer Institute, Boston

07601

NOT_YET_RECRUITING

John Theurer Cancer Ctr at Hackensack Univ. Med Ctr., Hackensack